To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients | Zendy

Marilee Carballo | Zendy; Roderick M. Quiros | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients

Author(s) -

Marilee Carballo,

Roderick M. Quiros

Publication year - 2012

Publication title -

journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.228

H-Index - 54

eISSN - 1687-8469

pISSN - 1687-8450

DOI - 10.1155/2012/707156

Subject(s) - medicine , thyroid cancer , thyroid , follicular thyroid cancer , radioiodine therapy , radioactive iodine , cancer , adjuvant , ablation therapy , thyroidectomy , radiology , papillary thyroid cancer , adjuvant therapy , oncology , prostate cancer

Radioactive iodine (RAI) is used in treatment of patients with differentiated papillary and follicular thyroid cancer. It is typically used after thyroidectomy, both as a means of imaging to detect residual thyroid tissue or metastatic disease, as well as a means of treatment by ablation if such tissue is found. In this paper, we discuss the indications for and the mechanisms of RAI in the treatment of patients with thyroid cancer. We discuss the attendant risks and benefits that come with its use, as well as techniques used to optimize its effectiveness as an imaging tool and a therapeutic modality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research